Lexitas Ocusun dose first patient in cataract pilot
Lexitas Ocusun dose first patient in a US pilot of ZOC2017217, an investigational lanosterol-derived eye drop for age-related cataract. Lexitas Pharma Services and Ocusun said enrollment began 14 July 2026 at North Bay Eye Associates in Petaluma, California. The study is registered on ClinicalTrials.gov as NCT07395986 and is meant to support a later Phase III program.
Contents10 sections
Key Takeaways
- Lexitas and Ocusun enrolled the first patient in a US pilot of ZOC2017217 for age-related cataract on 14 July 2026.
- The trial (NCT07395986) is a multicenter, randomized, double-masked, placebo-controlled pilot with about 40 planned participants.
- Subjects are to receive 0.4% ZOC2017217 or placebo twice daily for 24 weeks; primary completion is estimated for March 2027.
- Surgery remains the standard treatment for cataracts; this program is testing a topical pharmacologic approach before a planned pivotal Phase III.
ZOC2017217 pilot at a glance
| Field | Detail |
|---|---|
| Drug | ZOC2017217 (0.4% investigational ophthalmic solution; lanosterol-derived) |
| Companies | Ocusun (sponsor); Lexitas Pharma Services (ophthalmology CRO partner) |
| Indication | Age-related cataract |
| Trial ID | NCT07395986 |
| Design | Multicenter, randomized, double-masked, placebo-controlled US pilot (Phase 2 on CT.gov) |
| Size / dosing | ~40 subjects; 1:1 active vs placebo; BID both eyes for 24 weeks |
| Milestone | First patient enrolled 14 July 2026 (Petaluma, California) |
| Timeline | Start Feb 2026; primary completion est. Mar 2027; completion est. May 2027 |
What did Lexitas and Ocusun announce?
On 14 July 2026, Lexitas Pharma Services and Ocusun said they enrolled the first patient in an ongoing US pilot evaluating ZOC2017217 for age-related cataracts. Lexitas and Ocusun's 14 July PR Newswire release named North Bay Eye Associates in Petaluma, California, under Jason Bacharach, MD, as the first-patient site.
The companies describe the study as a multicenter, randomized, double-masked, placebo-controlled pilot intended to support an upcoming pivotal Phase III trial. Ocusun is a Guangzhou-based ophthalmic pharmaceutical company; Lexitas is a Durham, North Carolina–based ophthalmology CRO supporting US operations.
How is NCT07395986 designed?
ClinicalTrials.gov record NCT07395986 lists the sponsor as Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd. Status is recruiting. Estimated enrollment is 40. The registry classifies the study as Phase 2, interventional, with parallel assignment and quadruple masking (participant, care provider, investigator, and outcomes assessor).
Adults aged 50 years and older with age-related cataract are to be stratified by race and best-corrected distance visual acuity, then randomized 1:1 to active investigational product or placebo. Dosing is twice daily in both eyes for 24 weeks, with a short safety follow-up if ocular adverse events are ongoing at exit. The study eye is the qualified eye used for efficacy analyses. Estimated primary completion is March 2027; estimated study completion is May 2027.
What is ZOC2017217 meant to do?
ZOC2017217 is an investigational topical drop derived from lanosterol, a naturally occurring sterol. In the PR Newswire release, Ocusun said preclinical work showed improved antioxidant activity and reduced protein misfolding and aggregation tied to lens opacity. The company also cited an exploratory China study in which 50.0% to 86.4% of participants reached visual acuity of 20/40 or better 12 to 24 weeks after treatment. That China exploratory readout is company-reported and separate from the US pilot now enrolling.
No US pivotal efficacy result is available yet. The pilot's job is to generate controlled US data before a larger Phase III.
Why does a non-surgical cataract option matter?
Cataract is a leading cause of vision impairment worldwide. The World Health Organization lists cataract among the main causes of distance vision impairment or blindness, affecting an estimated 94 million people among those with addressable vision loss. WHO's blindness and vision impairment fact sheet also notes that one in two people globally who need cataract surgery still lack access.
In the United States, the National Eye Institute states that surgery is the treatment that removes cataracts and that more than half of Americans age 80 or older either have cataracts or have had cataract surgery. NEI's cataracts overview underscores how common age-related lens clouding is — and why a topical alternative, if proven, would be clinically meaningful. ZOC2017217 has not been shown in a completed US controlled trial to replace surgery.
What should clinicians watch next?
Near-term watch items are enrollment pace, safety signals during the 24-week dosing window, and whatever efficacy endpoints the sponsors elevate from the pilot into Phase III. The registry lists high-contrast best-corrected distance visual acuity bands and digitized cataract grading among entry criteria, so visual function and lens opacity measures are likely central.
Until controlled US results read out, ZOC2017217 remains investigational. Surgery stays the established standard for vision-impairing cataract.
Related NovaPharma coverage
- Moderna mRNA-1083 Phase 3 flu-COVID response
- J&J Phase 3 Tremfya ulcerative colitis data
- Sepsis AI algorithms and real-time data needs
Frequently Asked Questions
What trial did Lexitas and Ocusun start dosing?
A US multicenter, randomized, double-masked, placebo-controlled pilot study of ZOC2017217 eye drops in adults with age-related cataract. Lexitas Pharma Services and Ocusun said the first patient was enrolled on 14 July 2026 at North Bay Eye Associates in Petaluma, California. The study is registered as NCT07395986.
What is ZOC2017217?
ZOC2017217 is an investigational topical eye drop derived from lanosterol. Ocusun is developing it as a potential non-surgical option for age-related cataract. The US pilot is designed to inform a later pivotal Phase III program; ClinicalTrials.gov lists the pilot as Phase 2 with about 40 planned participants.
How is the NCT07395986 pilot designed?
About 40 adults aged 50 years and older with age-related cataract are to be randomized 1:1 to 0.4% ZOC2017217 or placebo, dosed in both eyes twice daily for 24 weeks. The registry lists the study as recruiting, with estimated primary completion in March 2027 and study completion in May 2027. Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd. is the sponsor.
Primary Sources
This article follows our editorial standards. Report a correction via editorial contact.
